Jayson Rieger - 25 Nov 2025 Form 4 Insider Report for Verrica Pharmaceuticals Inc. (VRCA)

Role: CEO and President, Director
Signature: /s/ Jayson Rieger
Issuer symbol: VRCA
Transactions as of: 25 Nov 2025
Net transactions value: +$400,114
Form type: 4
Filing time: 25 Nov 2025, 19:00:11 UTC
Previous filing: 18 Mar 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Rieger Jayson	CEO and President, Director	C/O VERRICA PHARMACEUTICALS INC., 44 W. GAY ST., SUITE 400, WEST CHESTER	/s/ Jayson Rieger	25 Nov 2025	0002043558

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VRCA	Common Stock	Purchase	$400,114	+94,311	+107%	$4.24	182,593	25 Nov 2025	Direct	F1
holding	VRCA	Common Stock						15	25 Nov 2025	By child	F1
holding	VRCA	Common Stock						230	25 Nov 2025	By trust	F1, F2
holding	VRCA	Common Stock						230	25 Nov 2025	By trust	F1, F2
holding	VRCA	Common Stock						230	25 Nov 2025	By trust	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VRCA	Series C Warrant (right to buy)	Purchase		+23,577			23,577	25 Nov 2025	Common Stock	23,577	$6.32	Direct	F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Effective July 24, 2025, the Issuer effected a 1-for-10 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split.
F2	These shares are held in separate trusts for the benefit of the Reporting Person's immediate family members. The Reporting Person is a co-trustee of each trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F3	Immediately exercisable.
F4	The reported securities are included within 94,311 investment units purchased by the Reporting Person for $4.2425 per investment unit. Each investment unit consists of one share of Common Stock and a Series C warrant for one fourth of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series C Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise.